Organigram Reports Health Canada Approval of Phase 2 Expansion

On March 6, 2018 Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQB: OGRMF), a leading licensed producer of medical marijuana based in Moncton, New Brunswick, announced that it had received Health Canada approval for the remaining 13 rooms of its 23 room Phase 2 expansion a week ahead of schedule. The Company expects harvests from the Phase 2 expansion to begin the third week of April.

The Phase 2 expansion will reportedly include significant improvements and efficiencies to the company’s cultivation and processing systems. Planned enhancements will include a fully automated irrigation system, automated potting, a fully automated waste destruction system and automated packaging. Organigram’s approach to production has been trending yields that are in some cases 50% higher than its previous estimates and the company fully anticipates this to continue with enhanced improvements in cultivation and environmental design in Phase 3 and Phase 4 as well as through achievements of economies of scale through optimization of its pre-vegetation and cloning processes.

According to Organigram CEO, Greg Engel, the company is, “seeing some harvest yields that are more than 400 grams per square foot a year and have witnessed the quality, density and size of flowers improve tremendously.” The company now expects that by early 2020 it will be producing over 110,000 kg/year from fully funded operations. Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada.